RWRuth C. Wilkins

Ruth C. Wilkins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ruth C. Wilkins has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Automated Cytogenetic Biodosimetry at Population-Scale

    by Peter K. Rogan, Eliseos J. Mucaki, Ben C. Shirley, Yanxin Li, Ruth C. Wilkins, Farrah Norton, Olga Sevriukova, Ngoc-Duy Pham, Ed Waller, Joan H. M. Knoll

    The dicentric chromosome (DC) assay accurately quantifies exposure to radiation; however, manual and semi-automated assignment of DCs has limited its use for a potential large-scale radiation incident. The Automated Dicentric Chromosome Identifier and Dose Estimator (ADCI) software automates unattended DC detection and determines radiation exposures, fulfilling IAEA criteria for triage biodosimetry. This study evaluates the throughput of high-performance ADCI (ADCI-HT) to stratify exposures of populations in 15 simulated population scale radiation exposures. ADCI-HT streamlines dose estimation using a supercomputer by optimal hierarchical scheduling of DC detection for varying numbers of samples and metaphase cell images in parallel on multiple processors. We evaluated processing times and accuracy of estimated exposures across census-defined populations. Image processing of 1744 samples on 16,384 CPUs required 1 h 11 min 23 s and radiation dose estimation based on DC frequencies required 32 sec. Processing of 40,000 samples at 10 exposures from five laboratories required 25 h and met IAEA criteria (dose estimates were within 0.5 Gy; median = 0.07). Geostatistically interpolated radiation exposure contours of simulated nuclear incidents were defined by samples exposed to clinically relevant exposure levels (1 and 2 Gy). Analysis of all exposed individuals with ADCI-HT required 0.6–7.4 days, depending on the population density of the simulation.


  • Open Access

    Prediction of the Acute or Late Radiation Toxicity Effects in Radiotherapy Patients Using Ex Vivo Induced Biodosimetric Markers: A Review

    by Volodymyr Vinnikov, Manoor Prakash Hande, Ruth Wilkins, Andrzej Wojcik, Eduardo Zubizarreta, Oleg Belyakov

    A search for effective methods for the assessment of patients’ individual response to radiation is one of the important tasks of clinical radiobiology. This review summarizes available data on the use of ex vivo cytogenetic markers, typically used for biodosimetry, for the prediction of individual clinical radiosensitivity (normal tissue toxicity, NTT) in cells of cancer patients undergoing therapeutic irradiation. In approximately 50% of the relevant reports, selected for the analysis in peer-reviewed international journals, the average ex vivo induced yield of these biodosimetric markers was higher in patients with severe reactions than in patients with a lower grade of NTT. Also, a significant correlation was sometimes found between the biodosimetric marker yield and the severity of acute or late NTT reactions at an individual level, but this observation was not unequivocally proven. A similar controversy of published results was found regarding the attempts to apply G2- and γH2AX foci assays for NTT prediction. A correlation between ex vivo cytogenetic biomarker yields and NTT occurred most frequently when chromosome aberrations (not micronuclei) were measured in lymphocytes (not fibroblasts) irradiated to relatively high doses (4–6 Gy, not 2 Gy) in patients with various grades of late (not early) radiotherapy (RT) morbidity. The limitations of existing approaches are discussed, and recommendations on the improvement of the ex vivo cytogenetic testing for NTT prediction are provided. However, the efficiency of these methods still needs to be validated in properly organized clinical trials involving large and verified patient cohorts.


  • Open Access

    Estimating partial body ionizing radiation exposure by automated cytogenetic biodosimetry

    by Ben C. Shirley, Joan H.M. Knoll, Jayne Moquet, Elizabeth Ainsbury, Pham Ngoc Duy, Farrah Norton, Ruth C. Wilkins, Peter K. Rogan

    Purpose: Inhomogeneous exposures to ionizing radiation can be detected and quantified with the Dicentric Chromosome Assay (DCA) of metaphase cells. Complete automation of interpretation of the DCA for whole body irradiation has significantly improved throughput without compromising accuracy, however low levels of residual false positive dicentric chromosomes (DCs) have confounded its application for partial body exposure determination. Materials and Methods: We describe a method of estimating and correcting for false positive DCs in digitally processed images of metaphase cells. Nearly all DCs detected in unirradiated calibration samples are introduced by digital image processing. DC frequencies of irradiated calibration samples and those exposed to unknown radiation levels are corrected subtracting this false positive fraction from each. In partial body exposures, the fraction of cells exposed, and radiation dose can be quantified after applying this modification of the contaminated Poisson method. Results: Dose estimates of three partially irradiated samples diverged 0.2 to 2.5 Gy from physical doses and irradiated cell fractions deviated by 2.3-15.8% from the known levels. Synthetic partial body samples comprised of unirradiated and 3 Gy samples from 4 laboratories were correctly discriminated as inhomogeneous by multiple criteria. Root mean squared errors of these dose estimates ranged from 0.52 to 1.14 Gy 2 and from 8.1 to 33.3% 2 for the fraction of cells irradiated. Conclusions: Automated DCA can differentiate whole-from partial-body radiation exposures and provides timely quantification of estimated whole-body equivalent dose. Biographical Note: Ben Shirley M.Sc. is Chief Software Architect, CytoGnomix Inc. Canada; Joan Knoll Ph.D. Dipl.ABMGG, FCCMG is Professor in Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, Canada and cofounder, CytoGnomix Inc.; Jayne Moquet Ph.D. is Principal Radiation Protection Scientist in the Cytogenetics Group, Public Health England; Elizabeth Ainsbury Ph.D. is Head, Cytogenetics Group and the Chromosome Dosimetry Service, Public Health England; Pham Ngoc Duy M.Sc. is deputy director of Biotechnology Center, Dalat Nuclear Research Institute, Vietnam; Farrah Norton M.Sc.is Research Scientist and Lead of the Biodosimetry emergency response and research capability at Canadian Nuclear Laboratories; Ruth Wilkins, Ph.D. is Research Scientist and Chief of the Ionizing Radiation Health Sciences Division at Health Canada, Ontario, Canada; and Peter K. Rogan Ph.D. is Professor of Biochemistry and Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, Canada, and President, CytoGnomix Inc.